EPTFE

How to improve the functional patency of ePTFE-based prostheses 392... 

The first series of femoro-popliteal shunts, including 15 patients suffering a severe lower limb arterite (level III, even IV) and for whom the saphenous vein could not be used, was reported by Campbell in 1976 [20] the patency rate at 8 months was 87%. These ePTFE prostheses made surgeons very enthusiastic and at least one of them, Veith [21], argued in their favour through an impressive... 

Considering the second requirement, that is, good dynamic mechanical properties ePTFE-based arterial prostheses must satisfy to improve their functional patency, there are not so many ways to reach this goal. Unfortunately, and due to the intrinsic mechanical characteristics of PTFE, the mechanical behaviour of these prostheses cannot be easily modified. However, different ways have been explored on the one hand, an optimisation of the design of the prostheses... 

C.C. Larsen, F. Kligman, K. Kottke-Marchant, R.E. Marchant, The effect of RGD fluorosurfactant polymer modification of ePTFE on endothelial cell adhesion, growth, and function. Biomaterials 27 (2006) 4846-4855. 

Polytetrafluoroethylene suture is composed of expanded polytetrafluoroethylene (ePTFE), resulting in a porous microstructure having longitudinally oriented nodes and fibrils. The suture is sold by W. L. Gore Associates, Inc. under the trade name Gore-Tex Suture. 

Class III Premarket Approval. Similar to a new drug approval, a premarket approval grants the applicant a license to market a specific well-characterized device. These devices are subject to the requirements of Section 515 of the Food, Drug, and Cosmetic Act. A post-amendment device is a device put in commercial distribution after May 28, 1976. If it is not substantially equivalent to a preamendment device it is automatically in Class III, and a premarket approval application (PMA) is required. The application must include reports of preclinical and clinical studies done in support of claims of safety and efficacy as well as any labeling claims made for the device. Once the PMA is submitted, the FDA determines whether the application includes the required information. If the PMA is suitable for scientific review, the FDA has 180 days from the filing date to approve or deny the application. Polybutester, polydioxanone, polyglyconate, and ePTFE sutures are all regulated as Class III devices. 

Kellar RS, Kleinert LB, Williams SK. Characterization of angiogenesis and inflammation surrounding ePTFE implanted on the epicardium. Journal of Biomedical Materials Research 2002, 61, 226-233. 

Salzmann DL, Kiemer LB, Berman SS, Williams SK. The effects of porosity on endothelialization of ePTFE implanted in subcutaneous and adipose tissue, journal of Biomedical Materials Research 1997, 34, 463 -76. 

Hou (35) 2005 aSpire ePTFE covered Pig carotid art SNP 54.5 ng/ stent Bare Yes ... 

Tarry, S.W. Henricksen, G. Prashad, M. Troeger, H. Integrity testing of EPTFE membrane filter vents. Ultra-pure Water 1993, 10 (8), 23-30. 

More recently, W. L. Gore Associates, Inc. [31] have used expanded polytetrafluoroethylene (ePTFE) porous films and PFSA resin solutions to produce a composite membrane. In this process, the PFSA solution was brushed onto both sides of the ePTFE film so as to impregnate and substantially occlude the interior volume of the film a nonionic surfactant (5%, w/v) was then added into the PFSA solution as a penetrant. The surfactant was removed by soaking in isopropanol after drying at 140 °C (this procedure was repeated several times so as to fully occlude the interior... 

---